Literature DB >> 17263807

Localized and generalized forms of blistering in junctional epidermolysis bullosa due to COL17A1 mutations in the Netherlands.

A M G Pasmooij1, H H Pas, G H L Jansen, H H Lemmink, M F Jonkman.   

Abstract

BACKGROUND: Mutations in the gene COL17A1 coding for type XVII collagen cause non-Herlitz junctional epidermolysis bullosa (nH-JEB).
OBJECTIVES: Here we give an overview of the genotype-phenotype correlation in 12 patients from the Netherlands with type XVII collagen-deficient nH-JEB. PATIENT AND METHODS: Family and personal history and clinical presentation were recorded from each patient, and skin biopsies of intact and bullous skin were taken for immunofluorescence and electron microscopy. The mutations were identified by analysing the patient's DNA isolated from peripheral blood cells.
RESULTS: DNA analysis identified five novel deletions: 1284delA, 1365delC, 3236delT, 3600-3601delCT and 4425delT. Interestingly, we identified a new patient, homozygous for 4425delT, with an exceptionally mild blistering phenotype. All together, three patients had more localized blistering confined to hands, lower legs and face, absent or very mild nail dystrophy, normal primary hair and sparse secondary hair. Nine patients had generalized blistering, nail dystrophy, sparse primary and absent secondary hair. All 12 patients had amelogenesis imperfecta (enamel pitting). Immunofluorescence (IF) antigen mapping with monoclonal antibodies 1A8C and 1D1 that bind to type XVII collagen, but not to its 97-kDa fragment was completely negative in patients with generalized blistering, whereas reduced in patients with localized blistering.
CONCLUSIONS: Our data reveal that in patients with COL17A1 mutations a localized nH-JEB phenotype can be differentiated from a generalized nH-JEB phenotype by IF antigen mapping. The data are important for genetic counselling at early age when the clinical phenotype is not yet clear.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17263807     DOI: 10.1111/j.1365-2133.2006.07730.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

1.  Hypertrophy-associated polymorphisms ascertained in a founder cohort applied to heart failure risk and mortality.

Authors:  Afshin Parsa; Yen-Pei C Chang; Reagan J Kelly; Mary C Corretti; Kathleen A Ryan; Shawn W Robinson; Stephen S Gottlieb; Sharon L R Kardia; Alan R Shuldiner; Stephen B Liggett
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

2.  LAMB3 mutations causing autosomal-dominant amelogenesis imperfecta.

Authors:  J W Kim; F Seymen; K E Lee; J Ko; M Yildirim; E B Tuna; K Gencay; T J Shin; H K Kyun; J P Simmer; J C-C Hu
Journal:  J Dent Res       Date:  2013-08-19       Impact factor: 6.116

Review 3.  A post-classical theory of enamel biomineralization… and why we need one.

Authors:  James P Simmer; Amelia S Richardson; Yuan-Yuan Hu; Charles E Smith; Jan Ching-Chun Hu
Journal:  Int J Oral Sci       Date:  2012-09-21       Impact factor: 6.344

4.  A genome-wide association study identifies five loci influencing facial morphology in Europeans.

Authors:  Fan Liu; Fedde van der Lijn; Claudia Schurmann; Gu Zhu; M Mallar Chakravarty; Pirro G Hysi; Andreas Wollstein; Oscar Lao; Marleen de Bruijne; M Arfan Ikram; Aad van der Lugt; Fernando Rivadeneira; André G Uitterlinden; Albert Hofman; Wiro J Niessen; Georg Homuth; Greig de Zubicaray; Katie L McMahon; Paul M Thompson; Amro Daboul; Ralf Puls; Katrin Hegenscheid; Liisa Bevan; Zdenka Pausova; Sarah E Medland; Grant W Montgomery; Margaret J Wright; Carol Wicking; Stefan Boehringer; Timothy D Spector; Tomáš Paus; Nicholas G Martin; Reiner Biffar; Manfred Kayser
Journal:  PLoS Genet       Date:  2012-09-13       Impact factor: 5.917

Review 5.  Amelogenesis Imperfecta; Genes, Proteins, and Pathways.

Authors:  Claire E L Smith; James A Poulter; Agne Antanaviciute; Jennifer Kirkham; Steven J Brookes; Chris F Inglehearn; Alan J Mighell
Journal:  Front Physiol       Date:  2017-06-26       Impact factor: 4.566

6.  Clinical practice guidelines: Oral health care for children and adults living with epidermolysis bullosa.

Authors:  Susanne Krämer; James Lucas; Francisca Gamboa; Miguel Peñarrocha Diago; David Peñarrocha Oltra; Marcelo Guzmán-Letelier; Sanchit Paul; Gustavo Molina; Lorena Sepúlveda; Ignacio Araya; Rubén Soto; Carolina Arriagada; Anne W Lucky; Jemima E Mellerio; Roger Cornwall; Fatimah Alsayer; Reinhard Schilke; Mark Adam Antal; Fernanda Castrillón; Camila Paredes; Maria Concepción Serrano; Victoria Clark
Journal:  Spec Care Dentist       Date:  2020-11

Review 7.  A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.

Authors:  Payal M Patel; Virginia A Jones; Christy T Behnam; Giovanni Di Zenzo; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2021-05-17

8.  A targeted next-generation sequencing assay for the molecular diagnosis of genetic disorders with orodental involvement.

Authors:  Megana K Prasad; Véronique Geoffroy; Serge Vicaire; Bernard Jost; Michael Dumas; Stéphanie Le Gras; Marzena Switala; Barbara Gasse; Virginie Laugel-Haushalter; Marie Paschaki; Bruno Leheup; Dominique Droz; Amelie Dalstein; Adeline Loing; Bruno Grollemund; Michèle Muller-Bolla; Séréna Lopez-Cazaux; Maryline Minoux; Sophie Jung; Frédéric Obry; Vincent Vogt; Jean-Luc Davideau; Tiphaine Davit-Beal; Anne-Sophie Kaiser; Ute Moog; Béatrice Richard; Jean-Jacques Morrier; Jean-Pierre Duprez; Sylvie Odent; Isabelle Bailleul-Forestier; Monique Marie Rousset; Laure Merametdijan; Annick Toutain; Clara Joseph; Fabienne Giuliano; Jean-Christophe Dahlet; Aymeric Courval; Mustapha El Alloussi; Samir Laouina; Sylvie Soskin; Nathalie Guffon; Anne Dieux; Bérénice Doray; Stephanie Feierabend; Emmanuelle Ginglinger; Benjamin Fournier; Muriel de la Dure Molla; Yves Alembik; Corinne Tardieu; François Clauss; Ariane Berdal; Corinne Stoetzel; Marie Cécile Manière; Hélène Dollfus; Agnès Bloch-Zupan
Journal:  J Med Genet       Date:  2015-10-26       Impact factor: 6.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.